Difference between revisions of "Hepatocyte nuclear factor-1beta"
Jump to navigation
Jump to search
(→Positive: fix typo) |
|||
| Line 6: | Line 6: | ||
Note: | Note: | ||
*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian | *CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal |authors=Mentrikoski MJ, Wendroth SM, Wick MR |title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin |journal=Appl Immunohistochem Mol Morphol |volume=22 |issue=9 |pages=635–41 |date=October 2014 |pmid=25279712 |doi=10.1097/PAI.0000000000000004 |url=}}</ref> | ||
==Negative== | ==Negative== | ||
Revision as of 19:36, 30 March 2021
Hepatocyte nuclear factor-1beta, abbreviated HNF-1beta and HNF-1β, is an immunostain that marks clear cell carcinoma of the ovary.
Positive
- Clear cell carcinoma of the ovary.
- Renal cell carcinomas - including clear cell renal cell carcinoma.[1][2]
Note:
- CA-125, RCCma, and CD10 can help distinguish clear cell renal cell carcinoma and Müllerian clear cell tumours.[3]
Negative
References
- ↑ Hanley KZ, Cohen C, Osunkoya AO (February 2017). "Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall". Appl. Immunohistochem. Mol. Morphol. 25 (2): 134–138. doi:10.1097/PAI.0000000000000279. PMID 26574638.
- ↑ Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH (March 2020). "Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes". Cancers (Basel) 12 (3). doi:10.3390/cancers12030602. PMC 7139472. PMID 32150988. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139472/.
- ↑ Mentrikoski MJ, Wendroth SM, Wick MR (October 2014). "Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin". Appl Immunohistochem Mol Morphol 22 (9): 635–41. doi:10.1097/PAI.0000000000000004. PMID 25279712.